|
AU2017205900A1
|
|
Therapeutic anti-CD9 antibody
|
|
WO2016209079A1
|
|
Aml antigens and uses thereof
|
|
EP3189077A2
|
|
Hepatitis c virus specific antibody
|
|
US2017008952A1
|
|
Means and methods for producing stable antibodies
|
|
AU2015200208A1
|
|
Means and methods for producing high affinity antibodies
|
|
MX2016008345A
|
|
Ex vivo antibody production.
|
|
AU2014367398A1
|
|
Means and methods for counteracting myeloproliferative or lymphoproliferative disorders
|
|
WO2015037992A1
|
|
Parechovirus specific antibodies
|
|
EP2785737A2
|
|
Influenza a virus specific antibodies
|
|
US2015004155A1
|
|
RSV G protein specific antibodies
|
|
AU2011334867A1
|
|
Means and methods for producing high affinity antibodies
|
|
CA2768207A1
|
|
Means and methods for producing high affinity antibodies
|
|
EP2454284A2
|
|
Gram-positive bacteria specific binding compounds
|
|
MX2012000625A
|
|
Gram-positive bacteria specific binding compounds.
|
|
EP1997830A1
|
|
RSV specific binding molecules and means for producing them
|
